DOACs use in kidney transplant recipients with atrial fibrillation was associated with lower risk of composite outcomes and kidney transplant rejection.
Do direct oral anticoagulants reduce the risk of composite outcomes and kidney transplant rejection in kidney transplant recipients with atrial fibrillation compared to Vitamin K antagonists?
In kidney transplant recipients with atrial fibrillation, DOACs are associated with a lower risk of adverse composite outcomes and transplant rejection compared to VKAs.
Absolute Event Rate: 0% vs 0%
In this real-world cohort of KTRs with AF, DOACs use was associated with lower risk of the composite outcome and kidney transplant rejection.
Rossi et al. (Sun,) reported a other. DOACs use in kidney transplant recipients with atrial fibrillation was associated with lower risk of composite outcomes and kidney transplant rejection.